However, higher degrees of IgG reactions against 15 protein, specifically, E, NSP1, NSP2, NSP4, NSP5, NSP7, NSP8, NSP9, NSP10, RdRp, NSP14, NSP15, NSP16, ORF9b and

Overall, our findings suggest that inhibition of the SHH signaling pathway is a potential therapeutic strategy for glioblastoma, and the combination of NVP-LDE-225 with FasL

Variations considered significant at *p< 0.05, **p < 0.01, and ***p < 0.001 respect to control, and # p< 0.05, ## p < 0.01, and